Pharmacotherapy for tic disorders aims to reduce tic severity enough to improve daily functioning and health-related quality of life rather than to eliminate symptoms. Expert consensus emphasizes patient-centered decision-making that integrates disease-specific quality of life measures with objective tic severity scales. Medications may be prioritized when tics cause significant impairment, pose medical risks, require rapid control, or coexist with treatable co-morbidities. Current guidelines rely largely on limited trials and expert opinion, with dopamine-modulating agents and alpha-2 agonists being most commonly used. Further research should focus on open questions about real-world effectiveness and generalizability of individual pharmacological agents.
Andrea E Cavanna (Sat,) studied this question.